| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2024-09-09 20:39:02 UTC |
|---|
| Updated at | 2024-09-09 20:39:02 UTC |
|---|
| NP-MRD ID | NP0333810 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Dexamethasone |
|---|
| Description | Glucocorticoid with potent antiinflammatory props. Not FDA approved for use in food-producing animals, but may be used illegally
Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. It is used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.; Dexamethasone can be used in the context of congenital adrenal hyperplasia, to prevent virilisation of a female fetus. If one or both parents are carriers of mutations to the CYP21 (CYP21A2) gene, the mother may start dexamethasone treatment within 7 weeks of conception. At the 12th week, a chorionic villus sample will determine whether the fetus is male (in which case the dexamethasone is stopped) or female. Subsequent DNA analysis can then reveal whether the female fetus is a carrier of the mutation, in which case dexamethasone treatment must continue until birth. The side-effects for the mother can be severe and the long-term impact on the child is not clear.; Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid hormones. It acts as an anti-inflammatory and immunosuppressant. Its potency is about 20-30 times that of hydrocortisone and 4-5 times of prednisone. |
|---|
| Structure | CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3 |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C22H29FO5 |
|---|
| Average Mass | 392.4670 Da |
|---|
| Monoisotopic Mass | 392.19990 Da |
|---|
| IUPAC Name | 9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-2H,3H,3aH,3bH,4H,5H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one |
|---|
| Traditional Name | betamethasone |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO |
|---|
| InChI Identifier | InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3 |
|---|
| InChI Key | UREBDLICKHMUKA-UHFFFAOYNA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| Not Available | | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | Not Available |
|---|
| Chemical Taxonomy |
|---|
| Description | This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Hydroxysteroids |
|---|
| Direct Parent | 21-hydroxysteroids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Progestogin-skeleton
- 21-hydroxysteroid
- Pregnane-skeleton
- 20-oxosteroid
- 3-oxo-delta-1,4-steroid
- 3-oxosteroid
- 17-hydroxysteroid
- 11-hydroxysteroid
- 9-halo-steroid
- Halo-steroid
- Oxosteroid
- Delta-1,4-steroid
- Alpha-hydroxy ketone
- Cyclic alcohol
- Tertiary alcohol
- Ketone
- Fluorohydrin
- Halohydrin
- Secondary alcohol
- Cyclic ketone
- Organooxygen compound
- Alcohol
- Primary alcohol
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organic oxygen compound
- Alkyl halide
- Alkyl fluoride
- Organohalogen compound
- Organofluoride
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Uslar T, Newman AJ, Tapia-Castillo A, Carvajal CA, Fardella CE, Allende F, Solari S, Tsai LC, Milks J, Cherney M, Stouffer DG, Auchus R, Brown JM, Baudrand R, Vaidya A: Progressive 11beta-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines. J Clin Endocrinol Metab. 2024 Sep 23:dgae663. doi: 10.1210/clinem/dgae663. [PubMed:39312227 ]
- Langer F, Binter M, Hu X, Hufendiek K, Meister R, Tode J, Framme C, Fuchs H: In vitro comparison of human and murine trabecular meshwork cells: implications for glaucoma research. Sci Rep. 2024 Sep 23;14(1):22002. doi: 10.1038/s41598-024-73057-9. [PubMed:39313534 ]
- Kinugasa F, Kajikawa S, Weng J, Ugawa T, Fushiki H, Yamanaka Y, Nagata M, Haggerty G, Akuzawa S, Nakazawa T, Suzuki H, Sawamoto T: Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. J Pharmacol Sci. 2024 Nov;156(3):161-170. doi: 10.1016/j.jphs.2024.08.005. Epub 2024 Aug 26. [PubMed:39313274 ]
- Mujtaba MA, Desai H, Ambekar A, Fule R, Pande S, Warsi MH, Elhassan GO, Taha M, Anwer K, Golghate TD: Development of chitosan/sodium carboxymethyl cellulose-based polyelectrolyte complex of dexamethasone for treatment of anterior uveitis. Biomed Mater. 2024 Oct 3;19(6). doi: 10.1088/1748-605X/ad7e6b. [PubMed:39312950 ]
- Kiristioglu MO, Ucan Gunduz G, Abdullayeva N, Doganay S, Yalcinbayir O: NONPHARMACOLOGICAL ASPECTS OF INTRAVITREAL DEXAMETHASONE IMPLANT INJECTIONS: A Retrospective Study of 3,430 Injections and Complications. Retina. 2025 Jan 1;45(1):95-106. doi: 10.1097/IAE.0000000000004270. [PubMed:39312882 ]
|
|---|